In vitro bioequivalence testing for topical ophthalmic suspension products (17of39) Complex Generics 

Darby Kozak from CDER’s Office of Generic Drugs discusses in vitro BE for generic topical ophthalmic
products: when, how and why. Kozak shares the regulatory background and when in vitro testing may be considered / recommended for demonstrating bioequivalence, current thinking on the information to support an in vitro approach, and GDUFA research and development of product-specific guidances for ophthalmic products.
-----------------------------
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
Upcoming training and free continuing education credits: www.fda.gov/cdersbia
CDER SBIA 2018 Playlist: • 2018 CDER Small Busine...
LinkedIn: / cder-small-business-an...
Training resources: www.fda.gov/cderbsbialearn
Twitter: / fda_drug_info
CDER small business e-mail update subscription: updates.fda.gov/subscriptionm...
Email: CDERSBIA@fda.hhs.gov
Phone: (301) 796-6707 I (866) 405-5367

Наука